ImmunityBio IBRX
NASDAQ IBRX
$10.28 +1.01 (+10.83%)
At close: Oct 2, 2026 · 4:00 PM EDT

ImmunityBio (IBRX) Return on Sales [ROS] (2014 - 2026)

Updated

ImmunityBio (IBRX) recorded Return on Sales [ROS] of -120.41% in Q2 2026, up 149.36 percentage points from -269.76% a year earlier and up 37.47 percentage points from the prior quarter.

Analysis

ImmunityBio (IBRX) Return on Sales [ROS] (2014 - 2026) Analysis & Trends

On a TTM basis, ImmunityBio's Return on Sales [ROS] came in at -151.88% as of Jun 30, 2026, up 352.30 percentage points year-over-year; for FY2025, it came in at -226.00%, up 2108.23 percentage points from FY2024.

  • Annual Return on Sales [ROS] has increased for three straight years, with a five-year change of +36283.09 percentage points (FY2020 to FY2025).
  • Across earlier years, Return on Sales [ROS] came in at -2334.23% in FY2024 (+55905.32 pp), -58239.55% in FY2023 (+88134.62 pp), -146374.17% in FY2022 (-111012.28 pp) and -35361.88% in FY2021 (+1147.21 pp).
  • The Q2 2026 figure is the highest quarterly Return on Sales [ROS] in data going back to Q1 2014.
  • On a year-over-year basis, Return on Sales [ROS] has increased for nine consecutive quarters, with an average year-over-year change of +50751.80 percentage points over the last eight quarters.
  • Peak year-over-year performance for Return on Sales [ROS] in the last five years was a gain of 654519.84 percentage points in Q1 2023, against a drop of 623453.85 percentage points in Q1 2022 at the low end.
  • Per Business Quant, the preceding three quarters came in at -157.88% (Q1 2026), -168.95% (Q4 2025) and -173.51% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,082.65 Bn 1,051.23 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 623.68 Bn 542.21 Bn 17.26 Bn 28.21%
3 AbbVie 459.43 Bn 432.59 Bn 12.70 Bn 37.86%
4 Merck 354.80 Bn 309.23 Bn 12.21 Bn -3.52%
5 Novartis Ag 269.16 Bn 225.03 Bn 11.24 Bn 32.97%
6 Astrazeneca 244.40 Bn 217.97 Bn 12.86 Bn 20.57%
7 Amgen 220.17 Bn 175.57 Bn 7.24 Bn 34.95%
8 Gilead Sciences 183.05 Bn 157.16 Bn 6.22 Bn -133.21%
9 Pfizer 160.27 Bn 107.22 Bn 10.94 Bn 28.37%
10 ImmunityBio 9.77 Bn 8.54 Bn 50.94 Mn -120.41%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -120.41%
Mar 31, 2026 -157.88%
Dec 31, 2025 -168.95%
Sep 30, 2025 -173.51%
Jun 30, 2025 -269.76%
Mar 31, 2025 -390.08%
Dec 31, 2024 -918.96%
Sep 30, 2024 -1,314.33%
Jun 30, 2024 -9,487.39%
Mar 31, 2024 -237,990.00%
Dec 31, 2023 -61,430.94%
Sep 30, 2023 -97,726.83%
Jun 30, 2023 -207,670.73%
Mar 31, 2023 -30,994.44%
Dec 31, 2022 -116,301.37%
Sep 30, 2022 -76,952.54%
Jun 30, 2022 -227,491.43%
Mar 31, 2022 -685,514.29%
Dec 31, 2021 -20,326.67%
Sep 30, 2021 -119,448.48%
API Access

ImmunityBio Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=IBRX&period=max&api_key=YOUR_API_KEY